ArticleGates open research2017
Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial.
Registry-linked trialAbstract read
In one paragraph
Article in Gates open research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02821832 (Using Biomarkers to Predict TB Treatment Duration), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Using Biomarkers to Predict TB Treatment Duration
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Subclinical tuberculosis: a meta-analysis of prevalence and scoping review of definitions, prevalence and clinical characteristics.European respiratory review : an official journal of the European Respiratory Society · 2024Pooled it
- Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions.Science translational medicine · 2026Trial
- Radiological and functional evidence of the bronchial spread of tuberculosis: an observational analysis.The Lancet. Microbe · 2021Trial
- Whole-body PET/CT reveals systemic dissemination in spinal tuberculosis: findings from the Spinal TB X cohort.Infection · 2026Article
- Optimisation and application of a T-cell antigen-specific activation assay as diagnostic and treatment-monitoring tool for tuberculosis.ERJ open research · 2026Article
- PET/CT imaging of tuberculosis lung lesions in marmosets treated with different drug regimens aligns with human clinical outcomes.Science translational medicine · 2026Article
- Transcript-Capture sequencing enriches mRNA ofNAR molecular medicine · 2026Article
- Transcript-Capture sequencing enriches mRNA ofbioRxiv : the preprint server for biology · 2025Article
- Article
- PET/CT guided tuberculosis treatment shortening: a randomized trial.medRxiv : the preprint server for health sciences · 2024Article
- Comparing gene expression profiles of adults with isolated spinal tuberculosis to disseminated spinal tuberculosis identified byJournal of orthopaedic surgery and research · 2024Article
- Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.Nature reviews. Drug discovery · 2024Review
- Does PET-CT Have a Role in the Evaluation of Tuberculosis Treatment in Phase 2 Clinical Trials?The Journal of infectious diseases · 2024Review
- Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes.Annals of the American Thoracic Society · 2023Article
- Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.BMC infectious diseases · 2023Article
- To treat or not to treat tuberculosis -clinical decision making in patients with previous pulmonary tuberculosis using 18F-FDG PET/CT.Respiratory medicine case reports · 2023Article
- A case report of persistent drug-sensitive pulmonary tuberculosis after treatment completion.BMC infectious diseases · 2022Article
- Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies.Clinical microbiology reviews · 2022Review
- End-point definition and trial design to advance tuberculosis vaccine development.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Visualizing the dynamics of tuberculosis pathology using molecular imaging.The Journal of clinical investigation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Ray Y ChenTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID https://orcid.org/0000-0001-6344-1442
Laura E ViaTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Lori E DoddBiostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Gerhard WalzlSouth Africa Department of Science and Technology - National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Stephanus T MalherbeSouth Africa Department of Science and Technology - National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
André G LoxtonSouth Africa Department of Science and Technology - National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Rodney DawsonDivision of Pulmonology, Department of Medicine, University Of Cape Town Lung Institute, University of Cape Town (UCT), Cape Town, South Africa.
Robert J WilkinsonWellcome Centre for Infectious Diseases Research in Africa,Institute of Infectious Disease and Molecular Medicine, University of Cape Town (UCT), Cape Town, South Africa.ORCID https://orcid.org/0000-0002-2753-1800
Friedrich ThienemannWellcome Centre for Infectious Diseases Research in Africa,Institute of Infectious Disease and Molecular Medicine, University of Cape Town (UCT), Cape Town, South Africa.
Michele TamerisSouth African Tuberculosis Vaccine Initiative, University of Cape Town (UCT), Cape Town, South Africa.ORCID https://orcid.org/0000-0002-7983-7203
Mark HatherillSouth African Tuberculosis Vaccine Initiative, University of Cape Town (UCT), Cape Town, South Africa.
Andreas H DiaconTASK Applied Science and Stellenbosch University, Cape Town, South Africa.
Xin LiuHenan Provincial Chest Hospital, Zhengzhou, Henan, China.
Jin XingHenan Provincial Institute of Tuberculosis and Prevention, Henan Center for Disease Control, Zhengzhou, Henan, China.
Xiaowei JinXinmi City Institute of Tuberculosis Prevention and Control, Xinmi, Henan, China.
Zhenya MaKaifeng City Institute of Tuberculosis Prevention and Control, Kaifeng, Henan, China.
Shouguo PanZhongmu County Health and Epidemic Prevention Station, Zhongmu, Henan, China.
Guolong ZhangHenan Provincial Institute of Tuberculosis and Prevention, Henan Center for Disease Control, Zhengzhou, Henan, China.
Qian GaoFudan University, Shanghai, China.
Qi JiangFudan University, Shanghai, China.
Hong ZhuSino-US Tuberculosis Collaborative Research Program, Zhengzhou, Henan, China.
Lili LiangTASK Applied Science and Stellenbosch University, Cape Town, South Africa.
Hongfei DuanBeijing Chest Hospital, Beijing, China.
Taeksun SongInstitute of Infectious Disease and Molecular Medicine, University of Cape Town (UCT), Cape Town, South Africa.
David AllandDivision of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
Michael TartakovskyOffice of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Alex RosenthalOffice of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Christopher WhalenOffice of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Michael DuvenhageOffice of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Ying CaiTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Lisa C GoldfederTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Kriti AroraTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Bronwyn SmithSouth Africa Department of Science and Technology - National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Jill WinterCatalysis Foundation for Health, Emeryville, CA, USA.
Clifton E Barry IiiTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Predict TB Study Group
Funding
International Tuberculosis Research in ChinaZIAAI001081 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARRY, CLIFTON · 2010 to 2025
$12.2MBiology and Biosignatures of Anti-Tuberculosis Treatment ResponseU01AI115619 · NIAID · COLORADO STATE UNIVERSITY · PI BELISLE, JOHN T · 2015 to 2019
$3.1MMedical Research Council MC_U117588499NIAID NIH HHS U01 AI115619Wellcome Trust
Abstract
trial registrationNCT02821832.
Indexed as
biomarkerscycle thresholddrug sensitiveGeneXpertMERMPET/CTpulmonary tuberculosistreatment shortening
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02821832ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.